Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
C426384-1ml
|
1ml |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$87.90
|
|
VEGFR3 Selective Inhibitors
| Synonyms | Cediranib maleate | 857036-77-2 | Cediranib (maleate) | AZD-2171 maleate | AZD2171 MALEATE | Cediranib maleat | 68AYS9A614 | 857036-77-2 (maleate) | 4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline maleate | Quinazoline, 4-((4-fl |
|---|---|
| Specifications & Purity | 10mM in DMSO |
| Biochemical and Physiological Mechanisms | Cediranib Maleate (AZD-2171) is the maleate salt of Cediranib, which is a potent inhibitor of VEGFR with IC50 of <1 nM and also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM. |
| Storage Temp | Store at -80°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
Information Cediranib Maleate (AZD-2171) is the maleate salt of Cediranib, which is a potent inhibitor ofVEGFRwith IC50 of <1 nM and also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM. Targets VEGFR2/KDR (HUVECs); c-Kit (HUVECs); c-Kit (HUVECs); VEGFR3/FLT4 (HUVECs); VEGFR1/FLT1 (HUVECs) 29716,0.5 nM; 2 nM; 2 nM; <=3 nM; 5 nM In vitro In recombinant kinase assays, cediranib inhibits VEGFR-1 kinase activity (IC50 = 5 nmol/L) within a similar concentration range to VEGFR-2 and VEGFR-3 (IC50 values of <0.1 and ≤3 nmol/L). It shows selectivity against other kinases. Cediranib has similar potency against c-Kit when compared with VEGFR-2 in phosphorylation assays but less potency against PDGFR-α and PDGFR-β, particularly in a PDGF-AA/PDGFR-α–driven tumor cell proliferation assay. Cediranib is inactive against wild-type Flt-3 (IC50 value >1 μmol/L) and had marginal activity versus FGFR-1 and -4 (IC50 values of 0.35 and 2.17 μmol/L, respectively). In vivo Phosphorylation of wild-type c-Kit in NCI-H526 tumor xenografts was reduced markedly following oral administration of cediranib (≥1.5 mg/kg/d) to tumor-bearing nude mice. |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic oxygen compounds |
| Class | Organooxygen compounds |
| Subclass | Ethers |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Diarylethers |
| Alternative Parents | Quinazolines Indoles Anisoles Alkyl aryl ethers Unsaturated fatty acids Aryl fluorides Dicarboxylic acids and derivatives Substituted pyrroles N-alkylpyrrolidines Pyrimidines and pyrimidine derivatives Heteroaromatic compounds Trialkylamines Azacyclic compounds Carboxylic acids Hydrocarbon derivatives Carbonyl compounds Organic oxides Organofluorides |
| Molecular Framework | Not available |
| Substituents | Diaryl ether - Quinazoline - Indole - Indole or derivatives - Anisole - Phenol ether - Alkyl aryl ether - Aryl fluoride - Aryl halide - Dicarboxylic acid or derivatives - Fatty acyl - Pyrimidine - Fatty acid - Substituted pyrrole - Unsaturated fatty acid - N-alkylpyrrolidine - Benzenoid - Pyrrolidine - Pyrrole - Heteroaromatic compound - Tertiary aliphatic amine - Tertiary amine - Azacycle - Organoheterocyclic compound - Carboxylic acid derivative - Carboxylic acid - Organonitrogen compound - Organic oxide - Organic nitrogen compound - Amine - Carbonyl group - Hydrocarbon derivative - Organohalogen compound - Organofluoride - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups. |
| External Descriptors | Not available |
|
|
|
| ALogP | 1.765 |
|---|---|
| HBD Count | 1 |
| Rotatable Bond | 10 |
| IUPAC Name | (Z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline |
|---|---|
| INCHI | InChI=1S/C25H27FN4O3.C4H4O4/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30;5-3(6)1-2-4(7)8/h6-7,12-15,29H,3-5,8-11H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1- |
| InChIKey | JRMGHBVACUJCRP-BTJKTKAUSA-N |
| Smiles | CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5.C(=CC(=O)O)C(=O)O |
| Isomeric SMILES | CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5.C(=C\C(=O)O)\C(=O)O |
| PubChem CID | 11226834 |
| Molecular Weight | 566.58 |
| Sensitivity | moisture sensitive |
|---|---|
| DMSO(mg / mL) Max Solubility | 100 |
| DMSO(mM) Max Solubility | 176.497581983127 |
| Water(mg / mL) Max Solubility | <1 |
| Molecular Weight | 566.600 g/mol |
| XLogP3 | |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 10 |
| Exact Mass | 566.218 Da |
| Monoisotopic Mass | 566.218 Da |
| Topological Polar Surface Area | 147.000 Ų |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 743.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 1 |
| Covalently-Bonded Unit Count | 2 |